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Abstract: 
 
This report presents the results from an historical case series of cytotoxic drug extravasations 
managed by saline washout; its purpose is to assess the efficacy of the procedure based on 
patient outcome. 89 patients were identified as having experienced a vesicant or exfoliant 
extravasation from incident reports filed over a 10 year period, from 1st April 2001 – 31st 
March 2011. Outcome was measured against the need for further surgical treatment being 
required. Of the 89 cases assessed for efficacy of saline washout one patient experienced a 
wound infection which was treated effectively with oral antibiotics. There were no other 
complications reported and no patients required further treatment with surgical debridement. 
The majority of patients had no deferral of treatment as chemotherapy could be continued in 
their unaffected arm immediately following saline washout procedure. For patients where 
cannulation in their opposite arm for continuation of treatment was not advisable 
chemotherapy was delayed between 3 to 7 days. Hospitalisation as a result of the 
extravasation or subsequent treatment was not required in any of the 89 cases.  Results 
indicate that saline washout technique is a safe and effective management strategy for the 
treatment of both vesicant and exfoliant chemotherapy extravasation. 
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Main Text: 
 
Introduction 
 
Extravasation, the inadvertent administration of intravenous medications (chemotherapy) into 
the surrounding tissues rather than into the vascular pathway as intended (Allwood, Stanley 
and Wright 2002, Dougherty and Lister 2008, RCN 2010) has been characterised in the 
literature as a ‘dreaded complication of chemotherapy’ or a ‘catastrophe’ (Schrivers 2003 
p26, Thakur 2008 p145). The outcome of an ineffectually managed extravasation can be 
potentially devastating, due to the ability of some drugs to cause severe tissue destruction if 
extravasated (Ener et al 2004, Arroyo et al 2010, Roe 2011, Schulmeister 2011). With Gault 
(2003) being of the opinion that the long term complications associated with an extravasation 
injury can be more disabling than the primary disease. 
 
Over the past fifty years since the introduction of systemic chemotherapy as a treatment for 
the management of both solid and haematological malignancies there has been a continuous 
steady rise in its use. Recent statistics indicate that there are around 309,500 new cases of 
cancer (excluding non-melanoma skin cancer) diagnosed each year in the UK (Cancer 
Research UK 2011), with the vast majority of cases (75%) diagnosed in people over the age 
of 60 (Cancer Research UK 2011), therefore concurrent with our ageing population it can be 
expected that this figure will continue to rise. Parallel to this the use of chemotherapy in the 
United Kingdom has been shown to have increased by up to 60% over the 4 years from 2005 
– 2009 (DOH 2009). This increasing use of cytotoxic drug therapy, the increasing complexity 
and efficacy of chemotherapy regimens, the continuous introduction of new systemic anti 
cancer therapies resulting in cancer now being classified as a chronic illness, means that over 
1.8 million people now live ‘with and beyond a cancer diagnosis’ (DOH 2011b, p7). The 
associated fact that these people are now able to receive multiple courses of chemotherapy 
treatments over a number of years all impacts on the potential for the number of cytotoxic 
drug extravasations to increase.  
 
Add to this the recent rise in litigation cases relating to patient outcome following 
extravasation (Schulmeister 2008a, Dougherty 2010) and it becomes vital that institutions 
have access to a management strategy that is both clinically effective and cost effective. 
Despite this, controversy continues in regard to the most appropriate treatment and 
management strategies that should be employed when an extravasation does occur.  
 
It is acknowledged that whilst healthcare providers take every precaution to prevent 
extravasation, it can still occur despite the experience, skill and knowledge of the practitioner 
administering the cytotoxic chemotherapy (Dougherty 2010, Schulmeister 2011). 
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Consequently in order to improve practice, reduce the risk of extravasation and in turn the 
risk of litigation there is a clear consensus of opinion that the key factor in the effective 
management of extravasation is staff education, supported by up to date institutional policies 
and procedures in order to enable the early detection of extravasation and to facilitate prompt 
intervention (EONS 2007, UKONS 2008, Dougherty 2010, Schulmeister 2011). This 
conclusion is supported by the recently published chemotherapy measures (DOH 2011a) 
which specify that all clinical chemotherapy services must have policies and procedures in 
place to ensure staff administering chemotherapy have had their competency assessed 
(Measure no’s 11-3S-116, 11-3S-118) and that there should be policies and procedures in 
place for chemotherapy administration techniques (Measure no 11-3S-123) and for systemic 
therapy acute oncology presentations which include the recognition and treatment of 
cytotoxic extravasation (Measure no 11-3S-124). It should however be noted that due to the 
recognised lack of evidence these measures do not advocate which extravasation 
management strategy should be used.  
 
There are currently five documented management strategies that can be used following 
cytotoxic drug extravasation, dependant on the category of the extravasated drug, volume and 
site of extravasation, local expertise and historical practice within institutions. These are the 
conservative strategy of ‘watch and wait’, surgical intervention, the topical application of ice 
or heat, the use of various antidotes, or saline washout technique (Dougherty and Oakley 
2011, Schulmeister 2011, Steiert et al 2011). 
 
Within the author’s institution (a major Cancer Centre in South East England) saline washout 
technique as developed by Gault (1993) has been used as the sole management strategy for 
vesicant and exfoliant cytotoxic drug extravasation for over 10 years (Table 1). In light of the 
current controversy as to the optimum management strategy for cytotoxic drug extravasation, 
particularly in regard to the management of anthracycline extravasations, the opinion that 
there is a lack of published data to support the use of saline washout technique (Roe 2011) 
and the view that its success is limited (Schulmeister 2011), it was thought both prudent and 
appropriate to review the centres historical outcome data. Also, taking into account the 
opinion of Steiert et al (2011) that a lack of published data on the outcome of saline washout 
technique as a therapeutic option for cytotoxic drug extravasations means that it has ‘not yet 
achieved the level of clinical significance that it rightfully should’ (p243) this data will add to 
the limited body of knowledge currently available about the efficacy of saline washout 
technique based on patient outcome.  
 
Cancer Centre protocol for extravasation management  
 
Until October 2006, any patient who experienced a vesicant or exfoliant drug extravasation 
(Table 1) was referred immediately to the plastic surgery team on site at the Cancer Centre 
for saline washout procedure using the Gault technique; this meant that any extravasation was 
treated within a few hours of its occurrence.  
 
In his paper in 1993 Gault felt that saline washout was most effective if undertaken within 1 
hour of drug extravasation. There have however been no further studies to either support or 
refute this statement, with the study by Steiert et al (2011) documenting the maximum time to 
washout as being 14 hours, the protocol published by Dougherty and Oakley (2011) 
advocating referral for washout within 2 hours and Schulmeister (2011) quoting the ideal as 
being within 6 hours. The underlying rationale being to wash any DNA binding drug out of 
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the tissues before it is able to intercalate with the cell’s DNA, but yet again it has to be 
acknowledged that the exact time frame for this is unknown.  
 
In October 2006, the plastic surgery department was moved 27 miles ‘off site’ from the 
Cancer Centre to a local district general hospital (DGH), this move has resulted in patients 
having an unavoidable delay in time to treatment, with the minimum time between vesicant 
or exfoliant drug extravasation and saline washout being 4 hours and the maximum time to 
saline washout being 16 hours.   
 
It must be noted that the classification of these drugs can vary dependant on author and that 
as often acknowledged in the SmPC the pharmacological properties of some are still not fully 
understood, as a result drugs with conflicting classifications are marked with an asterisk *. 
 
Data collection 
 
All cytotoxic drug extravasation incidents that occur within the cancer centre are documented 
and a record kept by the Trust. This is in accordance with international recommendations 
(EONS 2007, UKONS 2008, Dougherty 2010, Schulmeister 2011) that data should routinely 
be collected from all patients who experience a cytotoxic drug extravasation during the 
intravenous administration of chemotherapy. All extravasations as identified from incident 
reports filed at the authors institution over a 10 year period, from 1st April 2001 – 31st March 
2011 were reviewed and 147 patients were initially identified as being reported to have 
experienced an extravasation of either a vesicant or exfoliant (group 4 or 5) chemotherapeutic 
agent (table 1). Data was then collected from the Trust incident forms and from annotations 
the patient’s medical notes. 
 
This number of reported extravasations was referenced against the total number of 
chemotherapy administration each year at the Cancer Centre and compared against the 
figures reported in the literature that 0.01% - 6.5% of all cytotoxic drug administrations’ will 
result in an extravasation (Albanell and Baselga 2000, Schulmeister 2011). Subsequently, the 
mean incident rate of extravasation at the Cancer Centre was calculated as being 0.36%.   
 
Method and outcome analysis measures 
 
Schulmeister (2011) and Mourisden (2007) both cite lack of diagnostic verification (punch 
biopsy and fluorescence microscopy) to confirm extravasation as their main criticism of other 
case series. As the use of punch biopsy is not recognised as being standard practice within the 
United Kingdom to confirm extravasation and as this is an historical case series, the diagnosis 
of extravasation was made following ‘standard practice’ for recognition of the immediate 
manifestations of an extravasation (Dougherty 2010, EONS 2007). Extravasation assessment 
criteria are shown in table 2.  
 
The utilisation of punch biopsy to confirm extravasation as an addition to practice would also 
have significant cost and training implications, including the cost of additional staff training 
to perform the punch biopsy, extra strain on staff workload and time, alongside the 
subsequent increase in laboratory costs.  
  
The effectiveness of saline washout was evaluated by reviewing the patients’ medical notes 
(all medical correspondence, clerking notes, nursing documentation and referral letters) and 
recording all entries with reference to the extravasation for up to twelve weeks following the 
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initial treatment with saline washout technique. The annotations were recorded using a pre 
defined data collection tool (Figure 1) and catalogued anonymously.  
 
Outcome was determined by grouping the results into three categories: No further treatment 
required, sequalae documented and surgical debridement required. As with the prospective 
multicentre studies published by Mourisden et al (2007), the outcome measure used was that 
the intervention be judged effective if the patient did not require surgery (surgical 
debridement) as a consequence of the extravasation (p548). 
 
Patient data  
 
Of the 147 patients initially identified, 7 patients were immediately excluded from the data 
analysis as 5 patients had been reported twice and 2 patients had been incorrectly reported 
with the extravasated drug not being a chemotherapeutic agent, plus a further 2 patients had 
presented with late symptoms not confirmed as being the result of an extravasation. A 
breakdown of the resulting 138 cases of extravasation by year is shown in table 3. Thirteen 
patients had not had saline washout procedure carried out as the clinicians had instead opted 
for a ‘watch and wait’ policy and a further 36 sets of notes had gone into storage off site and 
were therefore unavailable to review. This resulted in a total of 89 patients being included in 
the data analysis as assessable for outcome.  
 
Patient demographics 
 
The divide between male and female patients was similar, with 54% male (n=48) and 46% 
female (n=41) being included in the final analysis. There was a diverse age range from 18 to 
79 years; the mean age being 59 years and the median age 58 years.  
 
The extravasation of vesicant chemotherapy accounted for 38% (34 patients) with 55 patients 
(62%) treated for the extravasation of exfoliant chemotherapy. Epirubicin a DNA binding 
anthracycline accounted for 16 (18%) of all extravasations included in the data set. Tumour 
sites varied, with the majority of patients (30%) having a diagnosis of colorectal cancer and 
18% a diagnosis of breast cancer. Of the 34 patients who experienced a vesicant drug 
extravasation 23 were female (Tables 4 and 5).   
 
Location of treatment and mean time to intervention 
 
Of the total 89 patients, 36 had been treated by plastic surgeons ‘on-site’ at the cancer centre 
and 52 patients were treated ‘off-site’ 27 miles away by the on call plastic surgery team at the 
district general hospital (DGH). The time saline washout procedure had been carried out was 
only documented in the cancer centre notes for 29 cases. Only 7 of the 52 patients treated off 
site had the time of procedure recorded in the cancer centres medical notes. A referral letter 
would have been sent with the patient, to the plastic surgeons and the procedure documented 
in the patient’s surgical notes, however access was not requested from the DGH to examine 
patient’s surgical notes as part of this review. 
Of the 29 patients notes where time to treat had been documented the range was from 10 
minutes for a vesicant extravasation, to over 12 hours for two exfoliant extravasations. The 
mean time to treatment was 175 minutes, with a median time to treat of 130 minutes. 
 
Technique specified 
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The cancer centre has a recognised protocol used for saline washout technique specifying that 
the area should first be infiltrated with hyaluronidase and then flushed through with saline, 
but it does not specify the exact amount of saline to be used. This is subject to clinicians 
judgement, dependant on the size of extravasation noted, evidence of erythema, swelling, 
induration or volume of extravasate. The volume of saline used for the procedure was 
specified in 40 of the 89 cases, again as noted above this is due to the procedure being carried 
out ‘off site’ and annotations being made in the surgical notes.  However in the annotated 
notes it was found that the volume of saline used for the procedure varied from 50mls – 
1000mls, the average volume of saline used being 400mls. 
Outcome / Efficacy 
 
Patient outcome following use of saline washout technique was assessed from annotations 
made in the patient’s medical notes up to sixteen weeks following their extravasation (Table 
6). In accord with the criteria utilised by Mourisden et al (2007) to determine efficacy, use of 
saline washout technique proved 100% effective, i.e. none of the 89 patients had surgery as a 
consequence of the extravasation. In addition none of the 89 patients experienced any degree 
of tissue necrosis or had any permanent physical damage following the procedure and use of 
saline washout is not associated with any clinical toxicy. 
 
Sequalae 
 
In the DNA binding vesicant group managed by use of saline washout, three patients 
experienced some minor bruising which quickly resolved, one patient had some mild 
erythema noted at 3 week follow up and one patient had residual inflammation 16 weeks post 
washout which settled with no further problems noted. There were no other complications 
such as induration, exfoliation, ulcer development or tissue necrosis reported and no patients 
required surgery. 
 
In the non DNA binding vesicant group 4 patients experienced some mild tenderness and 
erythema for up to 14 days after the procedure, all of which resolved within 21 days. One 
patient experienced a wound infection 14 days after the procedure which was treated 
effectively with oral antibiotics. Surgical debridement was not required. 
 
In the exfoliant group 15 patients (27%) experienced mild sequalae ranging from minimal 
bruising (6 patients), tenderness and mild erythema (3 patients) and cellulitis (6 patients) for 
which 4 patients required treatment with oral antibiotics. No other complications such as 
exfoliation, ulceration or necrosis were reported and no patients required surgery. 
 
Length of delay to ongoing chemotherapy treatment 
 
The majority of patients had no deferral of treatment as chemotherapy could be continued in 
their unaffected arm immediately following saline washout procedure. Three patients 
declined the remainder of their treatment for this cycle but continued with no delay to 
subsequent cycles, one patient had a delay to the next cycle as a result of residual cellulitis 
and one patient refused further chemotherapy stopping at cycle 5 of a planned 6 cycles of 
treatment for metastatic breast cancer. 
Whilst it is acknowledged that supporting evidence is sparse, it is widely accepted that breast 
cancer patients who have undergone axillary node clearance should avoid cannulation on 
their affected side (Cole 2006) so for this reason cannulation in their opposite arm for 
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continuation of treatment was not an option. For these patients, their chemotherapy was 
therefore delayed between 3 to 7 days. One patient was delayed for 4 days to allow a central 
venous access device (CVAD) to be placed as further peripheral access was not possible. 
Hospitalisation as a result of the extravasation or subsequent treatment was not required in 
any of the 89 cases. 
 
 
 
 
Discussion 
 
Following the recent publications by Dougherty and Oakley (2011) and Steiert (2011) this 
historical case series further supports the view that saline washout technique is a safe and 
effective strategy for the management of cytotoxic drug extravasation. Whilst it must be 
acknowledged that it is impossible to directly compare results from various case series due to 
the unaccounted variables such as drug concentration, dose, site etc. the outcome measure 
used to determine acceptable and effective outcome in the studies by Steiert (2011), 
Dougherty and Oakley (2011) and Mourisden et al (2007 ) are all the same: Avoidance of 
further surgical intervention.  
 
In the case series report of Steiert et al (2011) none of the 13 patients assessed for efficacy of 
saline washout procedure (SWOP) following extravasation (which included 9 vesicant 
extravasations) had any further complications such as tissue ulceration or subcutaneous tissue 
necrosis.  
 
In the article by Dougherty and Oakley (2011), whilst not documenting the nature of the 
extravasated drugs, they report a total of 6 flush out procedures performed with no patients 
requiring further intervention from the plastics team or experiencing any permanent physical 
damage.  
 
Of the 89 extravasations (including 16 anthracycline extravasations) assessed for efficacy of 
saline washout procedure as reported in this paper, none had any further complications such 
as tissue ulceration or subcutaneous tissue necrosis or required further treatment with surgical 
debridement. 
 
It must however be recognised that saline washout technique should only be carried out by 
experienced Health Care Professionals who have been appropriately trained and assessed as 
competent in the procedure. Although as Dougherty and Oakley (2011) have demonstrated 
this procedure is no longer limited to plastic surgeons and therefore recommend it becomes 
embedded into chemotherapy nursing practice, being easily incorporated into an advanced 
nurse practitioners role.  
 
As awareness and access to saline washout technique increases it is important to recognise 
that there are varying methods of saline washout that have developed following the initial 
publication by David Gault in 1993, which could potentially result in the procedure becoming 
‘too adapted’ and risk it becoming less effective. It is therefore recommended that a full risk 
assessment should be completed when making a decision about the extravasation 
management strategy of choice and that where cancer networks do not have access to the 
necessary expertise required to undertake saline washout procedure the appropriate antidote 
should always be used.  
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The limitations of this historical data analysis are acknowledged. Being retrospective it is 
dependent on the clinician’s annotations within the medical notes to confirm the diagnosis of 
extravasation. No photographic evidence was available to support the diagnosis. There was a 
significant lack of documentation in regarding the procedures carried out off site. However 
despite the retrospective nature of the data, the efficacy of saline washout being judged 
entirely on the patient not requiring any surgical resection is the same outcome measure as 
used in publications reporting the efficacy of dexrazoxane in the management of 
anthracycline extravasation (Mourisden et al 2007, Tyson and Gay 2010, Fontaine et al 
2012). 
 
Conclusion 
 
It is recommended that further prospective studies would be useful to identify and grade 
residual soft tissue damage following intervention with any extravasation management 
strategy and to determine the impact this has on the patient. Also one key aspect that must be 
noted is that whilst Mourisden et al (2007) and Steiert et al (2011) document the toxicities 
and sequalae experienced following extravasation management, none of the sourced literature 
documents or alludes to the patient’s perspective in regard to outcome.  
 
In the current economic climate there is an increasing awareness of the need to improve 
understanding of the comparative clinical effectiveness of healthcare interventions, with the 
Department of Health (March 2010a) focusing on the drive to maximize quality and improve 
patient experience with its QIPP philosophy of how the NHS must do business. It is also 
recognised that in some circumstances the strength of randomised controlled trials has limited 
applicability (Olsen and Mc Ginness 2010) and the use of alternative research strategies and 
sources to inform practice are more appropriate. The DOH white paper Equity and 
Excellence: Liberating the NHS (2010b), whilst acknowledging that doctors and nurses must 
be able to use their professional judgement about what is right for patients, also advocates 
that clinicians ensure shared decision making and consider the information patients can 
utilize in making an informed choice about the treatment they receive, the guiding principle 
being ‘No decision about me, without me’. 
  
Therefore, taking into account the ethical and practical limitations of randomised clinical 
trials, resulting in research studies being unable to demonstrate a clinical superiority of either 
management strategy plus the government’s philosophy for healthcare provision, it is 
suggested that future studies should start to focus on exploring the patient’s experience of 
extravasation and its subsequent management in relation to the clinical outcome. 
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Table 1 Examples of cytotoxic drugs documented as having vesicant or exfoliant 
potential 
 
Vesicants – Group 5 classification Exfoliants – Group 4 classification 
Amsacrine *                                   (DNA Binding) Adarubicin 
Bendamustine * Cisplatin 
Carmustine Docetaxol (Taxotere) * 
Chlormethine                                 (DNA Binding) Liposomal Daunorubicin 
Dacarbazine Floxuridine 
Dactinomycin                                 (DNA Binding) Oxaliplatin * 
Daunorubicin                                 (DNA Binding) Topotecan 
Doxorubicin                                   (DNA Binding)  
Epirubicin                                      (DNA Binding)  
Idarubicin                                      (DNA Binding)  
Mitomycin                                     (DNA Binding)  
Mitoxantrone *                              (DNA Binding)  
Mechlorethamine                           (DNA Binding)  
Paclitaxel  
Streptozocin  
Trabectin                                        (DNA Binding)  
Treosulphan  
Vinblastine  
Vincristine  
Vindesine  
Vinorelbine  
Adapted from: 
Schrivers 2003, Schulmeister 2011, www.extravasation.org.uk and from http://www.medicines.org.uk/emc/ 
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Table 2  
Extravasation criteria 
Adapted from: European Oncology Nursing Society (EONS) Extravasation Guidelines Implementation Toolkit (2007),  
Dougherty L. Extravasation: Prevention, recognition and Management. Nursing Standard (2010) Vol 24, no 52, p 48-55 
Characteristic Flare reaction Vessel irritation Venous shock Extravasation 
Presenting 
symptoms 
Itchy blotches or hives Aching and tightness Muscular wall of blood 
vessel in spasm 
Tenderness, pain, stinging and /or 
burning during drug administration 
at the venepuncture site, non-coring 
needle injection site or CVAD entry 
/ exit site.  
Colouration Red raised blotches / 
diffuse  or irregular hive 
like erythema  
Dark discolouration or 
erythema tracking along the 
vessel ( if peripheral venous 
cannula in situ ) 
 Erythema around the venepuncture 
site, non-coring needle injection site 
or CVAD entry / exit site. (Not 
always present immediately) 
Swelling Unlikely Unlikely  Some oedema likely to be present 
(Often difficult to identify 
immediately) 
Blood return Usually remains if 
previously present 
Usually remains if 
previously present 
Often absent or lost if 
previously present. 
Often misleading as blood return 
can still be present if an 
extravasation has occurred. 
Loss of blood return if previously 
present may predispose 
extravasation. 
Other    Leakage of drug at or around the 
administration site 
Timing Usually appears suddenly 
and dissipates within 30-90 
minutes 
Usually appears within 
minutes after drug 
administration, although 
tracking may appear later in 
the process 
Usually appears 
immediately, but can 
occur at any time during 
the administration process 
Can occur at any time during the 
administration process 
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Table 3 
Reported extravasations by year (1st April – 31st March) 
 01-02 02-03 03-04 04-05 05-06 06-07 07-08 08-09 09-10 10-11 Total 
Vesicants            
Epirubicin 1 2 1 1 2 6 1 0 2 2 18 
Dacarbazine 0 0 0 1 0 0 1 0 0 2 4 
Mitomycin 0 0 0 0 0 0 0 0 0 0 0 
Paclitaxel 1 0 2 2 1 1 1 3 1 3 15 
Vinblastine 0 0 0 1 0 0 1 0 0 0 2 
Vincristine 0 0 0 0 0 1 0 0 0 0 1 
Vinorelbine 0 0 0 1 0 0 0 5 0 2 8 
Exfoliants            
Cisplatin 2 1 2 7 7 3 5 7 5 2 41 
Docetaxol 0 0 0 1 0 0 0 0 2 2 5 
Mitoxantrone 0 0 0 0 0 0 0 0 0 0 0 
Oxaliplatin 1 3 3 3 6 5 4 8 7 4 44 
Totals 5 6 8 17 16 16 13 23 17 17 138 
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Table 4  
Patient demographics  
Drug, category, tumour site and regimen Male  Female  Total 
Epirubicin  - DNA binding vesicant (5) 2 14 16 
Tumour Site /  Regimen   1 x Upper GI / EOX                         
1 x Colorectal / ECX 
3 x Breast / Single agent                  
9 x Breast / FEC                                    
2 x GI / ECX 
 
Dacarbazine - Non DNA binding  vesicant(5) 3 0 3 
Tumour Site / Regimen 2 x Hodgkin’s / ABVD                              
1 x Melanoma / single agent 
  
Paclitaxel -  Non DNA binding  vesicant(5) 2 6 8 
Tumour Site/ Regimen 1 x Melanoma / Taxol & Combre   
1 x Urothelial / Trial GTC 
5 x Ovarian / Taxol &  Carboplatin 
1 x Breast / Gem & Taxol 
 
Vinorelbine -  Non DNA binding  vesicant(5) 2 3 5 
Tumour Site/ Regimen 2 x Lung / VP 
  
1 x Breast / Vinor & Herceptin       
1 X Breast / single agent                  
1 x Lung / VP 
 
Vincristine -  Non DNA binding  vesicant(5) 1 0 1 
Tumour Site/ Regimen 1 x NHL / CHOP-R   
Vinblastine -  Non DNA binding  vesicant(5) 1 0 1 
Tumour Site/ Regimen 1 x Bladder / MVC   
Docetaxel  - Non DNA binding exfoliant(4) 2 1 3 
Tumour Site/ Regimen 2 x Prostate / single agent 1 x Breast / FEC-T   
Oxaliplatin -  Non DNA binding exfoliant(4) 22 5 27 
Tumour Site/ Regimen 11 x Colorectal / Xelox                    
8 x Colorectal / Folfox                     
2 x Rectal / Socrates                             
1 x Oesophageal / chemo-rad 
4 x Colorectal / Folfox                       
1 x Colorectal / Xelox 
 
Cisplatin -  Non DNA binding exfoliant(4) 13 12 25 
Tumour Site/ Regimen 1 x  SCLC / EP                                    
2 x Oesophageal / ECX                       
1 x Oesophageal / Herskovic              
2 x Germ cell / BEP                         
1 x Germ cell / TIP                             
1 x Mesothelioma / PP                        
1 x Lymphoma / R-ESHAP              
1 x HD / ESHAP                              
1 x NHL / ESHAP                                
1 x Bladder / MVC                               
1 x Tongue / Chemo - rad 
2 x Cervix / PMB                                 
2 x Cervix / chemo-rad                         
3 x Oesophageal / Herskovic                
2 x Germ cell / BEP                              
2 x Ovarian / EP                              
1 x NHL / ESHAP 
 
Total 48 41 89 
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Table 5 
Total number of vesicant and exfoliant extravasations  
Key: DNA Binding vesicants = category A, Non DNA binding vesicants = category B, Exfoliants = category C 
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Table 6 
Incidence of sequalae following saline washout 
Drug No reported 
Sequalae  
Short term complications  Surgical 
intervention 
required 
DNA Binding vesicant (n=16)      
Epirubicin(16 patients) 
11 patients 2 patients – minimal bruising 1 day post washout. Settled with no 
further problems noted.                                                                       1 
patient – slight residual bruising 1 week post washout. Settled with no 
further problems noted.                                                        1 patient – 
mild erythema to site 3 weeks post washout. Settled with no further 
problems noted.                                                        1 patient – minor 
inflammation at site noted 16 weeks post washout, but no induration, 
ulceration or tissue breakdown. Settled with no further problems noted. 
No surgical 
intervention 
required 
Non DNA Binding vesicant 
(n=18)                            
Dacarbazine(3 patients) 
Paclitaxel(8 patients) 
Vincristine(1 patients) 
Vinorelbine (5 patients) 
Vinblastine (1 patient) 
13 patients Dacarbazine:                                                                                          1 
patient – skin healed but tender 14 days post washout. Settled with no 
further problems noted.                                                          Paclitaxel:     
1 patient – some tenderness and erythema 1 day post washout. Settled 
with no further problems noted.                                       Vincristine:         
1 patient – mild redness noted 7 weeks post washout. Settled with no 
further problems noted.                                                       Vinorelbine:     
1 patient – area tender 12 days post washout, nil else of note, settled 
with no further problems.                                                             1 
patient – wound infection developed 2 weeks post washout. Treated 
with antibiotics. No further sequalae noted. 
No surgical 
intervention 
required 
Exfoliant (n= 55)                  
Docetaxel (3 patients) 
Cisplatin( 25 patients) 
Oxaliplatin( 27 patients) 
 
40 patients Docetaxel:                                                                                               1 
patient - Some cellulitis noted 10 days post washout. Settled with no 
further problems noted.                                                                          1 
patient– some cellulitis noted 3 weeks post washout. Settled with no 
further problems noted.                                                         Cisplatin:       
3 patients - arm bruised / tender 1 day post washout. Settled with no 
further problems noted.                                                                           2 
patients - minimal bruising 2 days post washout. Settled with no further 
problems noted.                                                            Oxaliplatin:            
1 patient – treated with oral antibiotics at 9 days post washout due to 
mild cellulitis. Some induration noted at 20 days post, no further 
complications documented.                                                                1 
patient – still some erythema and tenderness 12 days post washout, 
mild analgesia required. Settled with no further problems noted.                
1 patient – slight bruising, discolouration and ache14 days post 
washout. Settled with no further problems noted.                                   
1 patient – some erythema and swelling 15 days post washout. 28 days 
later – all settled.                                                                             2 
patients – cellulitis treated with oral antibiotics at 21 days post 
washout. Area remained inflamed (no desquamation) up to 35 days 
post washout, then settled with no further complications.                         
1 patient – slight soreness at site with intermittent swelling at 23 days 
post washout, able to perform all ADL. Settled with no further 
problems noted.                                                                              1 
patient – persistent cellulitis at 31 days post washout. Improvement 
No surgical 
intervention 
required 
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noted at 49 days with no further problems noted.  
 
 
 
 
 
 
 
 
 
 
Figure 1 
Data collection tool 
 
Date of extravasation: Time of extravasation 
Age: (at time of extravasation) Sex:     M          F  
Diagnosis: Treatment intent: Adjuvant,  Neo-adjuvant, 
Palliative 
Regimen: Extravasated drug: 
Cycle: Dose (mgs) 
Site of extravasation:      Wrist,          dorsum of hand,              forearm,              ACF,      
other 
Immediate action taken: Aspiration attempted,      Ice and elevate,         Heat and elevate, 
Documentation: 
Nursing 
 
 
 
 
 
 
Oncology team : 
 
 
 
 
 
 
 
 
Delay, interruption or deferral of treatment? 
   
Time seen by plastics team: Seen at:   Cancer Centre / DGH  
Treatment by plastics team as documented in notes: 
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Volume of saline used in washout: 
Hyaluronidase used: Yes / No 
Delay to treatment documented: 
Further documentation and dates: (continue overleaf) 
 
 
